Send to

Choose Destination
Curr Pharm Biotechnol. 2019 Mar 11. doi: 10.2174/1389201020666190311143554. [Epub ahead of print]

Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-Alcoholic Fatty Liver Disease.

Author information

Natural product research Institute, Korea Institute of Science and Technology, Gangneung. Korea.
Nodaji Co., Ltd., Pohang, Gyeongbuk. Korea.
Department of Biological Sciences, SungKyunKwan University, Suwon, Kyungki-do. Korea.
Department of Pathology, Gangneung Asan Hospital, University of ulsan College of medicine, Gangneung. Korea.


Red ginseng is a traditional medicine that has been used to treat numerous metabolic and inflammatory diseases. Probiotic administration has been established to have beneficial effects in non-alcoholic fatty liver disease (NAFLD). The purpose of this study was to determine whether a combination of Korean red ginseng (KRG) and probiotics could synergistically reduce NAFLD and liver inflammation compared with the effects reported for each individual product. db/db and C57BL/6 mice were fed a normal chow diet and high-fat diet (HFD), respectively, and were treated with KRG, probiotics, or both. Samples were examined for lipid content, kinase protein phosphorylation, and gene expression patterns. KRG- and probiotic-treated HFD-fed mice exhibited a reduction in body weight and a decrease in inflammatory cytokine secretion compared with the non-treated control mice. The same treatment was less successful in improving NAFLD parameters in the db/db mice while the combination of both products did not enhance their therapeutic potential. The results of this study indicate that KRG and probiotics administration ameliorated NAFLD symptoms in a mouse model of dyslipidemia by reducing weight gain and liver inflammation. Coadministration of both products did not enhance their efficacy, and further research should be conducted to clarify their mechanisms of action.


Korean red ginseng (KRG); liver function; non-alcoholic fatty liver disease (NAFLD); oral administration; probiotics

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center